Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 5/20 | 0.45 |
| ▸ | CNR2 | P34972 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 5/20 | 0.42 |
| ▸ | MMP2 | P08253 | 4/20 | 0.42 |
| ▸ | MMP1 | P03956 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3110661 | 1.00 | WDR5 (0.46) | WDR5CNR1CNR2MAPK1MAPK10 | |
| SCHEMBL3102177 | 0.85 | MMP9 (0.45) | MAPK1P2RX7NAMPTMMP9MMP2 | |
| SCHEMBL3093427 | 0.85 | MMP9 (0.45) | MAPK1P2RX7NAMPTMMP9MMP2 | |
| SCHEMBL3110646 | 0.85 | MMP9 (0.45) | MAPK1P2RX7NAMPTMMP9MMP2 | |
| SCHEMBL3106753 | 0.83 | NAMPT (0.58) | CNR1CNR2MAPK1P2RX7NAMPT | |
| SCHEMBL3114502 | 0.83 | NAMPT (0.58) | CNR1CNR2MAPK1P2RX7NAMPT | |
| SCHEMBL3101362 | 0.80 | TAS1R3 (0.57) | CNR1ALDH1A1 | |
| SCHEMBL3101304 | 0.78 | ALDH1A1 (0.67) | ALDH1A1 | |
| SCHEMBL31622392 | 0.74 | CNR1 (0.46) | CNR1CNR2MAPK1MAPK10P2RX7 | |
| SCHEMBL3112024 | 0.74 | NAMPT (0.51) | CNR1CNR2MAPK1MAPK10P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150105386-A1 | 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS | ABBVIE DEUTSCHLAND (DE) | 2015-04-16 | — | — | US | disclosed |
| US-8895749-B2 | 4-(4-pyridinyl)-benzamides and their use as rock activity modulators | ABBVIE INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20130310378-A1 | 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS | ABBVIE INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-8445686-B2 | 4-(4-pyridinyl)-benzamides and their use as rock activity modulators | ABBVIE INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20100273828-A1 | 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310378-A1 | 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS | GABRR3, ROCK1, ROCK2 | WDR5 2178/4885CNR1 72/4885CNR2 59/4885 |
| US-20150105386-A1 | 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS | GABRR3, ROCK1, ROCK2 | WDR5 2176/4885CNR1 74/4885CNR2 60/4885 |
| US-20100273828-A1 | 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS | GABRR3, ROCK1, ROCK2 | WDR5 2178/4885CNR1 72/4885CNR2 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.